Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models

BACKGROUND: Lurbinectedin is a novel anticancer agent currently undergoing late-stage (Phase II /III) clinical evaluation in platinum-resistant ovarian, BRCA1/2-mutated breast and small-cell lung cancer. Lurbinectedin is structurally related to trabectedin and it inhibits active transcription and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Belgiovine, Cristina, Bello, Ezia, Liguori, Manuela, Craparotta, Ilaria, Mannarino, Laura, Paracchini, Lara, Beltrame, Luca, Marchini, Sergio, Galmarini, Carlos M, Mantovani, Alberto, Frapolli, Roberta, Allavena, Paola, D'Incalci, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572168/
https://www.ncbi.nlm.nih.gov/pubmed/28683469
http://dx.doi.org/10.1038/bjc.2017.205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572168/
https://www.ncbi.nlm.nih.gov/pubmed/28683469
http://dx.doi.org/10.1038/bjc.2017.205

Ejemplares similares